A phase-1 clinical trial executed on LBCL patients using bispecific CAR T cells indicated that CD19/CD22 CAR T-cells exhibited favorable results in B-cell acute lymphoblastic leukemia patients with 82% MRD-CR and in LBCL patients with 62% ORR [63]. This evidence concerns the gene CD22 and B-cell acute lymphoblastic leukemia.